NASDAQ:ASMB - Assembly Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$43.29 +2.08 (+5.05 %)
(As of 05/27/2018 04:00 PM ET)
Previous Close$43.29
Today's Range$40.37 - $43.99
52-Week Range$18.60 - $67.36
Volume181,005 shs
Average Volume162,295 shs
Market Capitalization$889.65 million
P/E Ratio-17.96
Dividend YieldN/A
Beta0.79

About Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences logoAssembly Biosciences, Inc. operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States. It is involved in the development of core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. In addition, it engages in the development of product candidates for various disease indications, such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, non-alcoholic steatohepatitis, immuno-oncology, and clostridium difficile infections by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of selected microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.

Receive ASMB News and Ratings via Email

Sign-up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ASMB
CUSIP92282210
Phone317-210-9311

Debt

Debt-to-Equity RatioN/A
Current Ratio9.30
Quick Ratio9.30

Price-To-Earnings

Trailing P/E Ratio-17.96
Forward P/E Ratio-12.70
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.02 million
Price / Sales98.63
Cash FlowN/A
Price / CashN/A
Book Value$4.98 per share
Price / Book8.69

Profitability

EPS (Most Recent Fiscal Year)($2.41)
Net Income$-42,800,000.00
Net Margins-379.22%
Return on Equity-56.56%
Return on Assets-32.21%

Miscellaneous

Employees79
Outstanding Shares20,550,000

Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions

What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences Inc (NASDAQ:ASMB) issued its earnings results on Monday, May, 7th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.69) by $0.12. The biopharmaceutical company earned $3.57 million during the quarter, compared to analysts' expectations of $1.88 million. Assembly Biosciences had a negative return on equity of 56.56% and a negative net margin of 379.22%. View Assembly Biosciences' Earnings History.

What price target have analysts set for ASMB?

3 Wall Street analysts have issued 1-year price objectives for Assembly Biosciences' stock. Their predictions range from $45.00 to $75.00. On average, they expect Assembly Biosciences' share price to reach $56.6667 in the next twelve months. View Analyst Ratings for Assembly Biosciences.

Who are some of Assembly Biosciences' key competitors?

Who are Assembly Biosciences' key executives?

Assembly Biosciences' management team includes the folowing people:
  • Mr. Derek A. Small, Co-Founder, Pres, CEO & Director (Age 42)
  • Dr. Richard J. Colonno Ph.D., Chief Scientific Officer (Age 68)
  • Mr. Thomas E. Rollins, Exec. Officer (Age 62)
  • Mr. David J. Barrett CPA, Strategic Advisor Role (Age 42)
  • Dr. Miguel S. Barbosa Ph.D., Strategic Advisor (Age 60)

Has Assembly Biosciences been receiving favorable news coverage?

Press coverage about ASMB stock has been trending positive on Sunday, Accern Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Assembly Biosciences earned a news sentiment score of 0.27 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 47.38 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Assembly Biosciences' major shareholders?

Assembly Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include venBio Select Advisor LLC (5.32%), Rock Springs Capital Management LP (2.16%), Northern Trust Corp (1.09%), Lyon Street Capital LLC (0.68%), Victory Capital Management Inc. (0.60%) and JPMorgan Chase & Co. (0.53%). View Institutional Ownership Trends for Assembly Biosciences.

Which major investors are selling Assembly Biosciences stock?

ASMB stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, BNP Paribas Arbitrage SA, JPMorgan Chase & Co., A.R.T. Advisors LLC, Hsbc Holdings PLC, Rock Springs Capital Management LP, California Public Employees Retirement System and Dimensional Fund Advisors LP. View Insider Buying and Selling for Assembly Biosciences.

Which major investors are buying Assembly Biosciences stock?

ASMB stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Allianz Asset Management GmbH, Allianz Asset Management GmbH, venBio Select Advisor LLC, WINTON GROUP Ltd, Iguana Healthcare Management LLC, Lyon Street Capital LLC and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Assembly Biosciences.

How do I buy shares of Assembly Biosciences?

Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Assembly Biosciences' stock price today?

One share of ASMB stock can currently be purchased for approximately $43.29.

How big of a company is Assembly Biosciences?

Assembly Biosciences has a market capitalization of $889.65 million and generates $9.02 million in revenue each year. The biopharmaceutical company earns $-42,800,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Assembly Biosciences employs 79 workers across the globe.

How can I contact Assembly Biosciences?

Assembly Biosciences' mailing address is 11711 NORTH MERIDIAN STREET SUITE 310, CARMEL IN, 46032. The biopharmaceutical company can be reached via phone at 317-210-9311 or via email at [email protected]


MarketBeat Community Rating for Assembly Biosciences (ASMB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  252
MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote "Outperform" if you believe ASMB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASMB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Assembly Biosciences (NASDAQ:ASMB) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Assembly Biosciences in the last 12 months. Their average twelve-month price target is $56.6667, suggesting that the stock has a possible upside of 30.90%. The high price target for ASMB is $75.00 and the low price target for ASMB is $45.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.332.332.673.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $56.6667$53.3333$40.00$42.50
Price Target Upside: 30.90% upside9.81% upside10.93% downside31.09% upside

Assembly Biosciences (NASDAQ:ASMB) Consensus Price Target History

Price Target History for Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences (NASDAQ:ASMB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2018B. RileyLower Price TargetNeutral ➝ Neutral$45.00HighView Rating Details
4/13/2018Chardan CapitalDowngradeBuy ➝ Neutral$35.00 ➝ $50.00HighView Rating Details
3/8/2018Jefferies GroupBoost Price TargetBuy$75.00MediumView Rating Details
8/19/2016William BlairInitiated CoverageMarket Perform ➝ OutperformN/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Assembly Biosciences (NASDAQ:ASMB) Earnings History and Estimates Chart

Earnings by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences (NASDAQ:ASMB) Earnings Estimates

2018 EPS Consensus Estimate: ($3.70)
2019 EPS Consensus Estimate: ($2.71)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.96)($0.96)($0.96)
Q2 20183($0.95)($0.86)($0.90)
Q3 20183($0.95)($0.84)($0.90)
Q4 20183($0.95)($0.93)($0.94)
Q1 20192($1.02)($0.29)($0.66)
Q2 20192($1.05)($0.29)($0.67)
Q3 20192($1.08)($0.29)($0.69)
Q4 20192($1.10)($0.29)($0.70)

Assembly Biosciences (NASDAQ ASMB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018Q1 2018($0.6870)($0.8020)$1.88 million$3.57 millionViewN/AView Earnings Details
3/8/2018Q4 2017($0.16)$3.32 millionViewN/AView Earnings Details
11/1/2017Q3 2017($0.88)($0.71)$1.25 million$2.66 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.78)$2.36 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.03)($0.81)$12.50 million$0.68 millionViewN/AView Earnings Details
3/2/2017Q4 2016($0.67)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.67)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.59)ViewN/AView Earnings Details
5/10/2016Q1 2016($0.64)ViewN/AView Earnings Details
3/11/2016Q4 2015($0.45)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.38)ViewN/AView Earnings Details
8/13/2015Q2 2015($0.41)ViewN/AView Earnings Details
5/8/2015Q1 2015($0.64)ViewN/AView Earnings Details
3/16/2015Q4 2014($0.38)ViewN/AView Earnings Details
11/17/2014Q3 2014($0.49)($1.33)ViewN/AView Earnings Details
8/14/2014Q2 2014($0.55)($0.52)ViewN/AView Earnings Details
4/2/2014($0.28)($0.29)ViewN/AView Earnings Details
8/9/2013Q2 2013($1.10)($1.20)ViewN/AView Earnings Details
5/10/2013Q1 2013($1.10)($1.10)ViewN/AView Earnings Details
11/13/2012Q3 2012($1.80)($2.05)ViewN/AView Earnings Details
8/9/2012Q2 2012($2.80)($2.95)ViewN/AView Earnings Details
5/9/2012Q1 2012($2.65)($3.30)ViewN/AView Earnings Details
11/14/2011Q3 2011($2.45)($2.50)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Assembly Biosciences (NASDAQ:ASMB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Assembly Biosciences (NASDAQ ASMB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 18.20%
Institutional Ownership Percentage: 77.35%
Insider Trading History for Assembly Biosciences (NASDAQ:ASMB)
Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences (NASDAQ ASMB) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/1/2018William R RingoDirectorSell1,000$43.06$43,060.0020,465View SEC Filing  
4/2/2018William R RingoDirectorSell1,000$49.32$49,320.0020,465View SEC Filing  
3/1/2018William R RingoDirectorSell1,000$56.37$56,370.00View SEC Filing  
2/1/2018William R RingoDirectorSell1,000$46.86$46,860.00View SEC Filing  
1/2/2018William R RingoDirectorSell1,000$45.04$45,040.00View SEC Filing  
12/1/2017William R RingoDirectorSell1,000$49.37$49,370.0020,465View SEC Filing  
11/1/2017William R RingoDirectorSell1,000$29.55$29,550.00View SEC Filing  
10/16/2017William R RingoDirectorSell1,000$33.70$33,700.00View SEC Filing  
2/11/2016Derek A. SmallCEOBuy10,000$5.53$55,300.00634,391View SEC Filing  
5/27/2014Russell H EllisonCEOBuy13,000$0.92$11,960.00View SEC Filing  
5/23/2014David Jonathan BarrettCFOBuy6,980$0.86$6,002.80View SEC Filing  
5/23/2014Russell H EllisonCEOBuy20,000$0.91$18,200.00View SEC Filing  
5/21/2014Russell EllisonCEOBuy10,000$0.87$8,700.0025,000View SEC Filing  
5/20/2014David Jonathan BarrettCFOBuy40,000$0.88$35,200.0040,000View SEC Filing  
2/5/2013Russell H EllisonCEOBuy15,000$2.55$38,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Assembly Biosciences (NASDAQ ASMB) News Headlines

Source:
DateHeadline
Assembly Biosciences (ASMB) Expected to Announce Quarterly Sales of $3.30 MillionAssembly Biosciences (ASMB) Expected to Announce Quarterly Sales of $3.30 Million
www.americanbankingnews.com - May 25 at 2:36 AM
-$0.90 EPS Expected for Assembly Biosciences (ASMB) This Quarter-$0.90 EPS Expected for Assembly Biosciences (ASMB) This Quarter
www.americanbankingnews.com - May 23 at 5:15 PM
Assembly Biosciences (ASMB) Downgraded by Zacks Investment Research to "Sell"Assembly Biosciences (ASMB) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - May 10 at 5:36 PM
Assembly Biosciences (ASMB) Given Average Recommendation of "Hold" by BrokeragesAssembly Biosciences (ASMB) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 10 at 12:26 PM
Jefferies Group Research Analysts Decrease Earnings Estimates for Assembly Biosciences (ASMB)Jefferies Group Research Analysts Decrease Earnings Estimates for Assembly Biosciences (ASMB)
www.americanbankingnews.com - May 10 at 7:19 AM
Assembly Biosciences (ASMB) to Post Q2 2018 Earnings of ($0.86) Per Share, William Blair ForecastsAssembly Biosciences (ASMB) to Post Q2 2018 Earnings of ($0.86) Per Share, William Blair Forecasts
www.americanbankingnews.com - May 10 at 7:19 AM
Assembly Biosciences Forecasted to Earn Q2 2018 Earnings of ($0.95) Per Share (ASMB)Assembly Biosciences Forecasted to Earn Q2 2018 Earnings of ($0.95) Per Share (ASMB)
www.americanbankingnews.com - May 10 at 7:19 AM
B. Riley Lowers Assembly Biosciences (ASMB) Price Target to $42.00B. Riley Lowers Assembly Biosciences (ASMB) Price Target to $42.00
www.americanbankingnews.com - May 8 at 11:02 AM
Assembly Biosciences: 1Q Earnings SnapshotAssembly Biosciences: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 10:07 AM
Assembly Biosciences Announces First Quarter 2018 Financial ResultsAssembly Biosciences Announces First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 10:07 AM
Assembly Biosciences (ASMB) Announces Quarterly  Earnings ResultsAssembly Biosciences (ASMB) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 8 at 8:20 AM
Zacks: Brokerages Anticipate Assembly Biosciences (ASMB) Will Post Quarterly Sales of $1.88 MillionZacks: Brokerages Anticipate Assembly Biosciences (ASMB) Will Post Quarterly Sales of $1.88 Million
www.americanbankingnews.com - May 8 at 3:56 AM
Assembly Biosciences (ASMB) Expected to Announce Earnings of -$0.76 Per ShareAssembly Biosciences (ASMB) Expected to Announce Earnings of -$0.76 Per Share
www.americanbankingnews.com - May 6 at 9:37 AM
Assembly Biosciences (ASMB) Raised to "Buy" at ValuEngineAssembly Biosciences (ASMB) Raised to "Buy" at ValuEngine
www.americanbankingnews.com - May 4 at 12:21 AM
Insider Selling: Assembly Biosciences (ASMB) Director Sells 1,000 Shares of StockInsider Selling: Assembly Biosciences (ASMB) Director Sells 1,000 Shares of Stock
www.americanbankingnews.com - May 2 at 4:34 PM
 Brokerages Expect Assembly Biosciences (ASMB) Will Post Quarterly Sales of $1.88 Million Brokerages Expect Assembly Biosciences (ASMB) Will Post Quarterly Sales of $1.88 Million
www.americanbankingnews.com - April 21 at 4:52 AM
 Analysts Anticipate Assembly Biosciences (ASMB) Will Announce Earnings of -$0.76 Per Share Analysts Anticipate Assembly Biosciences (ASMB) Will Announce Earnings of -$0.76 Per Share
www.americanbankingnews.com - April 19 at 5:19 AM
Assembly Biosciences (ASMB) Lowered to Sell at BidaskClubAssembly Biosciences (ASMB) Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 18 at 10:42 AM
Assembly Biosciences (ASMB) Receives Consensus Rating of "Hold" from AnalystsAssembly Biosciences (ASMB) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 15 at 7:15 AM
BidaskClub Upgrades Assembly Biosciences (ASMB) to "Sell"BidaskClub Upgrades Assembly Biosciences (ASMB) to "Sell"
www.americanbankingnews.com - April 13 at 5:29 PM
Chardan: Assembly Biosciences Hep B Antiviral Data Positive, But Undifferentiated From Competitor Johnson & JohnsonChardan: Assembly Biosciences Hep B Antiviral Data 'Positive,' But Undifferentiated From Competitor Johnson & Johnson
finance.yahoo.com - April 13 at 3:46 PM
Assembly Biosciences (ASMB) Downgraded by Chardan Capital to "Neutral"Assembly Biosciences (ASMB) Downgraded by Chardan Capital to "Neutral"
www.americanbankingnews.com - April 13 at 10:37 AM
Assembly Bios lead candidate shows positive action in early-stage HBV studiesAssembly Bio's lead candidate shows positive action in early-stage HBV studies
seekingalpha.com - April 12 at 11:19 AM
Was Assembly Biosciences Inc’s (NASDAQ:ASMB) Earnings Growth Better Than The Industry’s?Was Assembly Biosciences Inc’s (NASDAQ:ASMB) Earnings Growth Better Than The Industry’s?
finance.yahoo.com - April 12 at 11:19 AM
Assembly Biosciences (ASMB) Upgraded at BidaskClubAssembly Biosciences (ASMB) Upgraded at BidaskClub
www.americanbankingnews.com - April 12 at 10:22 AM
Assembly Biosciences to Host Conference Call on April 12 to Review ABI-H0731 Interim Phase 1b DataAssembly Biosciences to Host Conference Call on April 12 to Review ABI-H0731 Interim Phase 1b Data
www.nasdaq.com - April 11 at 11:00 AM
Assembly Bio conference call tomorrow to review ABI-H0731 dataAssembly Bio conference call tomorrow to review ABI-H0731 data
seekingalpha.com - April 11 at 11:00 AM
Assembly Biosciences (ASMB) Cut to Sell at BidaskClubAssembly Biosciences (ASMB) Cut to Sell at BidaskClub
www.americanbankingnews.com - April 4 at 9:55 AM
Assembly Biosciences (ASMB) Expected to Post Quarterly Sales of $1.88 MillionAssembly Biosciences (ASMB) Expected to Post Quarterly Sales of $1.88 Million
www.americanbankingnews.com - April 4 at 4:28 AM
Assembly Biosciences (ASMB) Says ABI-H0731 Phase 1b Interim Data Accepted as a Late-Breaker Poster at EASLAssembly Biosciences (ASMB) Says ABI-H0731 Phase 1b Interim Data Accepted as a Late-Breaker Poster at EASL
www.streetinsider.com - April 3 at 10:42 AM
Assembly Biosciences Appoints Jackie Papkoff, PhD, Senior Vice President, Chief Scientific Officer MicrobiomeAssembly Biosciences Appoints Jackie Papkoff, PhD, Senior Vice President, Chief Scientific Officer Microbiome
finance.yahoo.com - April 3 at 10:42 AM
William R. Ringo Sells 1,000 Shares of Assembly Biosciences (ASMB) StockWilliam R. Ringo Sells 1,000 Shares of Assembly Biosciences (ASMB) Stock
www.americanbankingnews.com - April 2 at 10:41 PM
Active-Investors: Blog Exposure - Assembly Biosciences to Present ABI-H0731 Phase-1b Interim Data at The International Liver CongressActive-Investors: Blog Exposure - Assembly Biosciences to Present ABI-H0731 Phase-1b Interim Data at The International Liver Congress
www.finanznachrichten.de - April 2 at 10:47 AM
Assembly Biosciences Inc (ASMB) Expected to Announce Earnings of -$0.79 Per ShareAssembly Biosciences Inc (ASMB) Expected to Announce Earnings of -$0.79 Per Share
www.americanbankingnews.com - April 2 at 5:12 AM
Jefferies Group Initiates Coverage on Assembly Biosciences (ASMB)Jefferies Group Initiates Coverage on Assembly Biosciences (ASMB)
www.americanbankingnews.com - April 1 at 10:48 AM
Assembly Biosciences (ASMB) & Blueprint Medicines (BPMC) Financial SurveyAssembly Biosciences (ASMB) & Blueprint Medicines (BPMC) Financial Survey
www.americanbankingnews.com - March 31 at 7:50 AM
Assembly Biosciences Inc (ASMB) Short Interest UpdateAssembly Biosciences Inc (ASMB) Short Interest Update
www.americanbankingnews.com - March 31 at 3:18 AM
Assembly Biosciences Sees Unusually High Options Volume (ASMB)Assembly Biosciences Sees Unusually High Options Volume (ASMB)
www.americanbankingnews.com - March 30 at 7:07 AM
Assembly Biosciences (ASMB) Upgraded to "Buy" at BidaskClubAssembly Biosciences (ASMB) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - March 26 at 3:13 PM
Assembly Biosciences (ASMB) Downgraded by BidaskClub to BuyAssembly Biosciences (ASMB) Downgraded by BidaskClub to Buy
www.americanbankingnews.com - March 23 at 8:28 PM
Assembly Biosciences Inc (ASMB) Given Average Rating of "Buy" by AnalystsAssembly Biosciences Inc (ASMB) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - March 21 at 10:44 AM
$1.68 Million in Sales Expected for Assembly Biosciences Inc (ASMB) This Quarter$1.68 Million in Sales Expected for Assembly Biosciences Inc (ASMB) This Quarter
www.americanbankingnews.com - March 18 at 9:28 AM
BidaskClub Upgrades Assembly Biosciences (ASMB) to Strong-BuyBidaskClub Upgrades Assembly Biosciences (ASMB) to Strong-Buy
www.americanbankingnews.com - March 17 at 7:16 PM
Assembly Biosciences (ASMB) Downgraded by Zacks Investment ResearchAssembly Biosciences (ASMB) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 14 at 5:32 PM
Assembly Biosciences Target of Unusually Large Options Trading (ASMB)Assembly Biosciences Target of Unusually Large Options Trading (ASMB)
www.americanbankingnews.com - March 14 at 7:33 AM
Assembly Biosciences (ASMB) Stock Rating Upgraded by Zacks Investment ResearchAssembly Biosciences (ASMB) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 13 at 5:48 PM
Assembly Biosciences Announces Additions to Management Team and Board of DirectorsAssembly Biosciences Announces Additions to Management Team and Board of Directors
finance.yahoo.com - March 12 at 9:16 AM
Assembly Biosciences Inc Expected to Earn Q1 2019 Earnings of ($0.82) Per Share (ASMB)Assembly Biosciences Inc Expected to Earn Q1 2019 Earnings of ($0.82) Per Share (ASMB)
www.americanbankingnews.com - March 12 at 7:15 AM
Assembly Biosciences Inc to Post Q2 2018 Earnings of ($0.77) Per Share, Jefferies Group Forecasts (ASMB)Assembly Biosciences Inc to Post Q2 2018 Earnings of ($0.77) Per Share, Jefferies Group Forecasts (ASMB)
www.americanbankingnews.com - March 12 at 3:40 AM
Assembly Biosciences (ASMB) PT Raised to $75.00 at Jefferies GroupAssembly Biosciences (ASMB) PT Raised to $75.00 at Jefferies Group
www.americanbankingnews.com - March 8 at 6:34 PM

SEC Filings

Assembly Biosciences (NASDAQ:ASMB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Assembly Biosciences (NASDAQ:ASMB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Assembly Biosciences (NASDAQ ASMB) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.